All Articles
The FDA has a regulatory function, which is probably best kept without looking at the costs of the medicines. The role is probably best for an independent HTA organization, like NICE. In Europe, the role of the EMA and of the HTA organization are 2 separate things, and that model works very well there. Read More ›
In today’s environment, there is no way the oncologist can avoid understanding the cost and the outcome issue if we’re going to help our patients evaluate what the regimens we’re recommending or the total treatment course; toxicity, short- and long-term, outcome; and what their cost is going to be. Read More ›
At this point, Foundation Medicine is exclusively an oncology company, but our next-generation sequencing technique, which can deep sequence hundreds of genes with world class laboratory capability and world class computational biology capability, certainly has potential applicability. Read More ›
Cancer is basically a disease of the genome. We know that most cancers are caused by changes at the DNA level, whether it’s caused by radiation, cigarette smoking, or unknown factors. DNA changes are really what drive cancer. Read More ›
Cost is a societal factor in the provision of medicines. Oncologists should work in the best interests of their patients and provide the treatments that give patients the most benefit, the fewest side effects, and the best chances of survival. Read More ›
A large part of what we need to do at Foundation Medicine is educate the physician, and the patients, that a test like ours is available, today, to give them a full information about their DNA, and what drives the cancer. Read More ›
As an oncologist who’s practiced for 35 years in the community where I really know my patients, when you listen to patients, they want to be actively involved they and their family, or a combination. Read More ›